TrueMark Investments LLC Increases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

TrueMark Investments LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 112.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,717 shares of the biopharmaceutical company’s stock after buying an additional 11,513 shares during the period. TrueMark Investments LLC’s holdings in Gilead Sciences were worth $2,006,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Kingsview Wealth Management LLC grew its holdings in Gilead Sciences by 8.9% in the 3rd quarter. Kingsview Wealth Management LLC now owns 19,923 shares of the biopharmaceutical company’s stock valued at $1,670,000 after buying an additional 1,628 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Gilead Sciences by 79.2% in the third quarter. Larson Financial Group LLC now owns 7,835 shares of the biopharmaceutical company’s stock valued at $657,000 after purchasing an additional 3,464 shares during the period. Independent Advisor Alliance raised its stake in Gilead Sciences by 1.2% during the third quarter. Independent Advisor Alliance now owns 23,730 shares of the biopharmaceutical company’s stock worth $1,990,000 after purchasing an additional 270 shares during the period. Truvestments Capital LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at about $126,000. Finally, FMR LLC grew its stake in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after buying an additional 14,680,161 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 302,785 shares of company stock worth $30,503,250. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $107.89 on Wednesday. The company has a market cap of $134.36 billion, a P/E ratio of 291.59, a PEG ratio of 0.71 and a beta of 0.21. The firm has a fifty day moving average price of $104.35 and a 200 day moving average price of $94.36. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.93%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on GILD shares. Bank of America lifted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Morgan Stanley upped their target price on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, March 11th. Finally, Piper Sandler lifted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.